TABLE 3.
Relationship Between EEG Features and Drug Resistance Stratified by Sleep and Wakefulness
| Feature | Responsive Patients With Feature, N (%) |
Resistant Patients With Feature, N (%) |
OR of Resistant-To-Responsive (95% CI) |
P |
|---|---|---|---|---|
| GSW awake | 51 (70.8) | 22 (71.0) | 1.0 (0.4–2.5) | 1.0 |
| GSW asleep | 47 (65.3) | 26 (83.9) | 2.8 (0.9–8.1) | 0.06 |
| PSW awake | 19 (26.4) | 14 (45.2) | 2.3 (1.0–5.5) | 0.07 |
| PSW asleep | 35 (48.6) | 18 (58.1) | 1.5 (0.6–3.4) | 0.40 |
| GPT awake | 3 (4.2) | 5 (16.1) | 4.4 (1.0–19.8) | 0.05 |
| GPT asleep | 6 (8.3) | 8 (25.8) | 3.8 (1.2–12.2) | 0.03 |
| GPFA awake | 4 (5.6) | 4 (12.9) | 2.5 (0.6–10.8) | 0.24 |
| GPFA asleep | 1 (1.4) | 4 (12.9) | 10.5 (1.1–98.4) | 0.03 |
| GPT or GPFA awake | 4 (5.6) | 6 (19.4) | 4.1 (1.1–15.7) | 0.06 |
| GPT or GPFA asleep | 6 (8.3) | 9 (29.0) | 4.5 (1.4–14.1) | 0.01 |
| GLVFA awake | 0 (0.0) | 0 (0.0) | — | — |
| GLVFA asleep | 0 (0.0) | 2 (6.5) | — | 0.09 |
| Focal discharges awake | 0 (0.0) | 3 (9.7) | — | 0.03 |
| Focal discharges asleep | 1 (1.4) | 0 (0.0) | — | 1.0 |
| Focal slowing awake | 3 (4.2) | 2 (6.5) | 1.6 (0.3–10.0) | 0.64 |
| Focal slowing asleep | 0 (0.0) | 0 (0.0) | — | — |
A higher OR implies greater prevalence of the feature in drug-resistant patients.
95% CI, 95% confidence interval; GLVFA, generalized low-voltage fast activity; GPFA, generalized paroxysmal fast activity; GPT, generalized polyspike train; GSW, generalized spike–wave; OR, odds ratio; PSW, polyspike-and-wave; —, not estimable.